Business Wire

BACARDI

25.3.2020 18:38:07 CET | Business Wire | Press release

Share
From USA to France and From UK to Mexico, Bacardi Diverts Global Production to Increase Hand Sanitizer Supply for Local Communities

Family-owned Bacardi has expanded its commitment across countries and brands to help produce more than 267,000 gallons (1.1 million liters) of hand sanitizers, as worldwide demand continues to exceed supply in efforts to reduce the risk of COVID-19. This week, eight Bacardi-owned manufacturing sites across the United States, Mexico, France, England, Italy and Scotland are joining the efforts, following last week’s announcement that Bacardi in Puerto Rico would supply alcohol to make hand sanitizers. Across the sites, Bacardi is diverting its global production power, resources and processes to supply the much-needed alcohol essential for the increased production of hand sanitizers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200325005615/en/

Bacardi is also playing a part in donating these products to local organizations and emergency responders, as well as its employees and contractors. In addition, the company is providing alcohol at cost to select partner companies looking to ramp up their production of hand sanitizers for commercial sale. These temporary, emergency actions at all locations will not disrupt the supply of brands in the Bacardi portfolio.

“Over our 158-year history, we have risen to many challenges and we are doing the same again in response to COVID-19,” said Jean-Marc Lambert, SVP Global Operations for Bacardi. “All our brands and partners involved in this initiative will help people most in need benefit from the supply of these hand sanitizers. Our goal is to make a very real difference in the fight against COVID-19.”

The current list of sites providing support either immediately or in the coming week are:

  • BACARDÍ rum in Puerto Rico – partnered with Puerto Rico based manufacturer Olein Refinery to provide raw materials that will enable the production of more than 1.7M units of 10-ounce (300 ml) hand sanitizers. Donated product to local USPS, firefighters, police and non-profit Somos Unidos (United Way);
  • Bacardi Bottling Corporation in Jacksonville, FL, USA – is planning to help produce approximately 23,000 gallons (87,000 liters) to make 120,000 units of 25-ounce (750 ml) bottles hand sanitizer for donation to local hospitals, firefighters and police. In addition, the team will supply 7,600 gallons (29,000 liters) to nearby manufacturers.
  • BACARDÍ rum in Tultitlán, Mexico – supplying more than 5,200 gallons (20,000 liters) of alcohol to nearby manufacturer, Grupo Sterk, to help increase production of hand sanitizer by approximately 6,300 gallons (24,000 liters), of which 2,100 gallons (8,000 liters) will be donated by Bacardi to local communities in Tultitlán, Arandas and Atotonilco;
  • GREY GOOSE® vodka in Cognac, France – will supply 7,600 gallons (29,000 liters) of alcohol per day to French companies to increase supply of hand sanitizers by 9,500 gallons (36,000 liters) for local pharmacies, hospitals and the emergency services;
  • BOMBAY SAPPHIRE® gin in Hampshire, England – is helping to produce a small quantity of hand sanitizers that will be donated to local doctors, chemists and care homes;
  • MARTINI in Pessione, Italy – is supplying alcohol for the production of 1,000 7-ounce (200ml) hand sanitizers for the local community, Red Cross and local emergency services;
  • DEWAR’S® Blended Scotch Whisky in Aberfeldy, Scotland – is helping to produce a small quantity of hand sanitizers for the Scottish Ambulance Association among other local community groups;
  • ANGEL’S ENVY® Kentucky Straight Bourbon in Louisville, KY, USA – is supplying nearly 1,000 gallons (3,800 liters) of alcohol to create approximately 16,000 8-ounce (250 ml) bottles of free hand sanitizers for first responders and healthcare professionals.

All hand sanitizers produced in collaboration with Bacardi contain more than the minimum alcohol content recommended by the World Health Organization for containing the spread of the virus.

About Bacardi

The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye